ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Well-Characterized Challenge Material of BSL-3 and BSL-4 Viruses
Retrieved on:
Monday, March 14, 2022
Research, Infectious Diseases, Genetics, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Virus, National Institute, NIAID, National, Senior, Infection, Collection, Vapour-phase-mediated antimicrobial activity, Research, Public health, Therapy, National Institute of Allergy and Infectious Diseases, Biosafety, Emergency, Science, NIH, WCCM, Drug discovery, Global health, Doctor of Philosophy, Division, History, CEO, BSL-4, Pharmaceutical industry, Vaccine, Microbiology, ATCC
ATCC will provide well-characterized Biosafety Level-3 (BSL-3) and BSL-4 viruses of public health concern, including those of pandemic or epidemic potential, to assist in developing medical countermeasures.
Key Points:
- ATCC will provide well-characterized Biosafety Level-3 (BSL-3) and BSL-4 viruses of public health concern, including those of pandemic or epidemic potential, to assist in developing medical countermeasures.
- ATCC will be contributing to NIAIDs mission of more than six decades to support the development of novel therapeutics and biological inhibitors to combat infectious diseases.
- Viruses with epidemic or pandemic potential require extensive investigational research toward the development of therapeutics.
- There is a critical need to improve production capacity while ensuring genomic homogeneity through well-characterized challenge material (WCCM) in therapeutic product development.